Question 1

Does Price T Rowe Associates own REGN stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Price T Rowe Associates holds 1,529,709 shares of REGN (Regeneron Pharmaceuticals), worth $953.8M.

Question 2

How many shares of REGN does Price T Rowe Associates own?

Accepted Answer

As of its Q2 2026 13F, Price T Rowe Associates holds 1,529,709 shares of REGN (Regeneron Pharmaceuticals).

Question 3

What is Price T Rowe Associates' REGN position worth?

Accepted Answer

As of its Q2 2026 13F, Price T Rowe Associates' REGN position is worth $953.8M.

Question 4

Is Price T Rowe Associates buying or selling REGN?

Accepted Answer

In Q2 2026, Price T Rowe Associates reduced its REGN position by 647,818 shares (-29.8%).

Question 5

When did Price T Rowe Associates first buy REGN?

Accepted Answer

Price T Rowe Associates already held REGN in its Q3 2019 13F, the earliest on record, and has listed it in 28 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	1.5M	-29.8%	$953.8M	0.1%	$622.81	0
2026-Q1	Increased	2.2M	+11.7%	$1.7B	0.2%	$770.59	43
2025-Q4	Increased	1.9M	+142.2%	$1.5B	0.2%	$768.90	62
2025-Q3	Increased	804,910	+5.0%	$452.6M	0.0%	$559.40	33
2025-Q2	Decreased	766,444	-64.8%	$402.4M	0.0%	$521.53	0
2025-Q1	Increased	2.2M	+4.3%	$1.4B	0.2%	$629.11	40
2024-Q4	Increased	2.1M	+63.5%	$1.5B	0.2%	$705.67	56
2024-Q3	Increased	1.3M	+36.7%	$1.3B	0.2%	$1,041.41	50

REGNShowing 8 of 28 quarters

REGN
Showing 8 of 28 quarters